Controversies in type 2 diabetes: An update

Australian Family Physician

Volumn 38, Issue 1-2, 2009, Pages 22-25

  Yeap, Bu B ^a  

^a UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE;

ARTICLE; HUMAN; NON INSULIN DEPENDENT DIABETES MELLITUS;

DIABETES MELLITUS, TYPE 2; HUMANS; THIAZOLIDINEDIONES;

EID: 60149090136     PISSN: 03008495     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (19)

1. Yeap BB. Type 2 diabetes mellitus - guidelines for initiating insulin therapy. Aust Fam Physician 2007;36:549-53.
2. Dormandy JA, Charbonnel B, Eckland DJA, et al. Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitazone Clinical Trial In macroVascular Eventsl: a randomised controlled trial. Lancet 2005;366:1279-89.
3. Lincoff AM, Wolski K, Nicholls SJ and Nissen SE. Pioglitazone and risk of cardiovascular events in patients with type 2 diabetes mellitus: a meta-analysis of randomized trials. JAMA 2007;298:1180-8.
4. Erdmann E, Charbonnel B, Wilcox RG, et al. Pioglitazone use anal heart failure in patients with type 2 diabetes and preexisting cardiovascular disease. Diabetes Care 2007;30:2773-8.
5. Theraeutic Goods Administration. Actos (pioglitazone hydrochloride) product information. Date of TGA approval: 20 November 2007.
6. Rosenstock J, Sugimoto D, Strange P, et al. Triple therapy in type 2 diabetes: insulin glargine or rosiglitazone added to combination therapy of sulfonylurea plus metformin in insulin-naive patients. Diabetes Care 2006;29:554-9.
7. Kahn SE, Haffner SM, Heise MA, et al. Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy. N Engl J Med 2086;355:2427-43.
8. Kahn SE, Zinmae B, Lachin JM, et al. Rosiglitazone-associated fractures in type 2 diabetes: an Analysis from A Diabetes Outcome Progression Trial (ADOPT). Diabetes Care 2098;31:845-51.
9. Grey A. Skeletal consequenees of thiazolidinedione therapy. Osteoporos Int 2008;19:129-J7.
10. Nissen SE, Wolski K. Effect of rosigtitazone on the risk of myocardial infarctien and death from cardiovascular causes. N Engl J Med 2007;398:2457-71.
11. Singh S, Loke YK and Furberg CD. Long-term risk of cardiovascular events with resiglitazone: a meta-analysis. JAMA 2007;298:1189-95.
12. Home PD, Pocock SJ, Beck-Nielsen H, et al. Rosiglitazone evaluated for cardiovas-colar outcomes - an interim analysis. N Engl J Med 2007;357:28-38.
13. Therapeutic Goods Administration. Avandia (rosiglitazone maleate) product information. Issue no. 13 (M). Date of TGA approval: 8 November 2007.
14. American Diabetes Association. Standards of medical care in diabetes - 2008. Diabetes Care 2008;31(Suppl 1):S12-54.
15. The ACCORD Study Group. Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial: design and methods. Am 3 Cardio12007;99(Suppl):211-33.
16. Gerstein HC, Riddle MC, Kendall DM, et al. Glycemia treatment strategies in the Action to Control Cardiovascular Risk in Diabetes (ACCOFID) trial. Am J Cardiol 2007;99(Suppl):34l-43.
17. National Heart, Lung and Blood Institute. Action to Control Cardiovascular Risk in Diabetes (ACCORD) Trial, February 6, 2008. Available at www.nhlbi.nih.gov/health/prof/heart/other/accord/index.htm [Accessed March 2008].
18. The Action to Control Cardiovascular Risk in Diabetes Study Group, Gerstein HC, Miller ME, et al. Effects of intensive glucose lowering in type 2 diabetes. New Engl J Med 2008;358:2545-59.
19. ADVANCE Collaborative Group, Patel A, MacMahon S, et al. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. New Engl J Med 2008;358:2560-72.